RAPT Therapeutics Inc (RAPT) - Total Liabilities
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has total liabilities worth $13.76 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RAPT Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See RAPT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
RAPT Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of RAPT Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PC Connection Inc
NASDAQ:CNXN
|
USA | $503.33 Million |
|
TBO Tek Ltd
NSE:TBOTEK
|
India | Rs58.86 Billion |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
China | CN¥562.67 Million |
|
Beijing Caishikou Department Store Co Ltd
SHG:605599
|
China | CN¥5.05 Billion |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
India | Rs17.76 Billion |
|
Greatech Technology Bhd
KLSE:0208
|
Malaysia | RM291.77 Million |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
USA | $637.29 Million |
|
German American Bancorp Inc
NASDAQ:GABC
|
USA | $7.21 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down RAPT Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RAPT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RAPT Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of RAPT Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $50.42 Million | +91.76% |
| 2023-12-31 | $26.29 Million | +24.95% |
| 2022-12-31 | $21.04 Million | +71.70% |
| 2021-12-31 | $12.26 Million | -17.13% |
| 2020-12-31 | $14.79 Million | +28.82% |
| 2019-12-31 | $11.48 Million | +104.58% |
| 2018-12-31 | $5.61 Million | -95.02% |
| 2017-12-31 | $112.80 Million | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more